Aims This study aimed to synthesize and evaluate novel furan derivatives as potential anticancer agents targeting colon cancer through VEGFR-2 inhibition and apoptosis induction.Materials and methods The cytotoxic activity of the synthesized compounds was assessed against human fibroblast (HSF) and colon cancer cell lines (HCT-116, Caco-2, and HT-29) using the MTT assay. VEGFR-2 inhibitory activity was determined in vitro, and immunocytochemistry was employed to evaluate VEGFR-2 expression. Apoptosis, cell cycle arrest, and migration inhibition were analyzed in Caco-2 cells. Molecular docking, molecular dynamics (MD) simulations, Density Functional Theory (DFT), and ADMET analyses were conducted to assess binding affinity, stability, and safety profiles.Results Compound 6 exhibited potent cytotoxicity against HT-29 (IC50 = 22.39 μM) and strong VEGFR-2 inhibition (IC50 = 0.28 ± 0.42 μM), comparable to sorafenib. It suppressed VEGFR-2 expression, induced G2/M cell cycle arrest, and promoted early and late apoptosis in 97% of treated Caco-2 cells. Upregulation of Bax and caspase-3, along with downregulation of Bcl-2, confirmed intrinsic apoptotic activation. Computational analyses supported compound 6’s stability and drug-likeness.Conclusions Compound 6 is a promising lead furan derivative with potent, selective anticancer activity against colon cancer via VEGFR-2 inhibition and apoptosis induction. Further, in vivo evaluation is warranted.
Abstract Background Colorectal cancer (CRC) is a type of cancer that affects the colon or rectum and occurs in individuals over the age of 50, although it can affect people of all ages. Quercetin is a flavonoid, which is a type of plant pigment with antioxidant and anti-inflammatory properties. Some studies have explored the potential of quercetin as an adjuvant therapy to enhance the effectiveness of chemotherapy or radiation therapy. Methodology In the proposed work, the nano-biomaterials of solid lipids such as stearic acid (SA) and tripalmitin (TpN) as well as the surfactants tween 80 and span 80 were used to prepare novel quercetin (QuR)-loaded-solid lipid nanoparticles (QuR-SLNs) for medical applications in colorectal cancer (CRC). The resulting bio-nano SLNs’ mean entrapment efficiency (EE) and particle size (PS) were optimized by Box–Behnken design (BBD) approach based on the response-like surface methodology (RSM). The variables include lipid ratio ( X 1 ), surfactant ratio ( X 2 ), QuR-to-lipid ratio ( X 3 ), the sonication time ( X 4 ), and the homogenization time ( X 5 ). Requirements on the maximum EE (%) and minimum PS (nm) were optimized for the preparation of QuR-SLN. Differential scanning calorimetry (DSC), X-ray diffraction (XRD) analysis, and scanning electron microscopy (SEM) were then used to analyze the optimized SLN and to find the crystalline state of QuR with lipid relationship. In addition, on the Caco-2 cells, at IC 50 (49 µM/mL), in vitro cytotoxicity was attained. Results The optimized QuR-SLN had practically spherical shapes, with % EE and a PS of 97.8 ± 1.16% and 132.16 ± 4.1 nm, respectively. In aqueous media, the degree of lipid crystallinity and the lipid modification was investigated, and the QuR incorporation and release patterns showed high correlations with both. The results showed that over 41.12 ± 1.6% of the bio-nano QuR-SLNs was released gradually over the course of 48 h, demonstrating effective QuR delayed release. Results on apoptotic observations indicate that apoptosis accounts for the majority of cell death, while necrosis, a type of cell death, constitutes a very minor portion. In conclusion, the prepared bio-nano QuR-SLNs might improve cytotoxicity and can act as an ideal carrier for the delivery of QuR and this preparation is used in the treatment of CRC.
A modular organ-on-a-chip (OOC) system has been developed, incorporating multiple epithelial barriers and perfused immune cells, and enabling the monitoring of the structure, integrity, and response of the barriers to activation.Additionally, it facilitates the examination of the complex interaction between multi-epithelial barriers with immune cells.Fig. 1a schematically illustrates the system, while Fig. 1b provides details of the microfluidic chip connections and Fig. 1c shows the fabricated system.Triple intestinal barriers and intestinal and epidermal barriers were integrated and characterized.OOC technology enables precise cell positioning and in vivo-like polarization, mimicking tissue organization.While organoids provide multicellular structures, more advanced methods are required to induce cellular assemblies and recreate the extracellular environment [1].Epithelial cell polarity, regulated by tight junction (TJ) formation, is crucial for various barriers [2].Microfluidic-based cell culture seamlessly integrates diverse cell types and organs into a unified fluidic circuit.We previously developed a reconfigurable fluidic routing system for inter-chip communication [3].Here, we present an enhanced system that effectively regulates multiple fluidic parameters and enables flexible chip-to-chip interconnections, allowing for fluid redirection across different spatial and temporal dimensions without compromising the flow in other chips.To demonstrate the versatility of MOOCS, three intestinal cell monolayers were integrated into a single fluidic circuit (Fig. 2a), and the TransEpithelial Electrical Resistance (TEER) resulting from the different linkages was measured.Both the individual and the interconnected monolayers displayed stable and increasing TEER values (Fig. 2b).After 20 days, the chips were interconnected, and 100 µL of DSS (5000 Da) was injected into one chip, leading to a decline in the total TEER.However, upon disconnecting the affected layer, the TEER returned to its initial level.This experimental setup allows for the execution of multiple experiments on the same cell culture by selectively eliminating the impacted cells.Then, three culture systems were tested: immune cells (THP-1), intestinal/immune cells (Caco-2/THP-1), and epidermal/immune cells (HaCaT/THP-1).Interactions with inflammation stimuli (LPS and DSS) were studied in interconnected/disconnected cellular systems (Fig. 3a).TEERs of disconnected layers increased over time (Fig. 3b).Caco-2 and HaCaT cultures were treated with DSS, showing significant cytotoxicity, especially in caco-2 cells (Fig. 3c).FITC-dextran (4 kDa) flux measurements revealed increased permeability when LPS was applied to Caco-2, HaCaT, or both layers (Fig. 3d).To investigate the response of the integrated cellular system, immune cells were activated by direct activation with LPS, activation through the caco-2 layer with LPS, activation through the HaCaT layer with DNCB, and activation through both layers with LPS and DNCB, respectively.IL-6 and IL-8 expression were measured in the basolateral compartment.Both LPS and DNCB induced significant immune cell responses, with direct treatment showing a higher inflammatory response compared to treatment through the caco-2/HaCaT layers.These findings highlight the successful integration of epithelial cell layers and their interaction with immune cells, providing a valuable model for studying drug screening.This system allows for flexible integration strategies of diverse cellular systems, enabling the investigation of cellular interactions when stimulated through various routes.
Journal of Biomolecular Structure and Dynamics · مجلد 41 (21) · 11535-11550
A new set of quinoline and isatine derivatives were synthesized as antiangiogenic VEGFR-2 inhibitors. On a biological level, the in vitro ability of the obtained candidates to inhibit VEGFR-2 was found to be strong with IC50 values in the range of 76.64–175.50 nM. To investigate the cytotoxicity and safety, all compounds were tested against a panel of four cancer cell lines (A549, Caco2, HepG2 and MDA) as well as two normal cell lines (Vero and WI-38). Interestingly, compound 12 exhibited noticeable cytotoxicity against A549, Caco2 and MDA with IC50 values of 5.40, 0.58 and 0.94 µM, respectively. These results were better and comparable to that of doxorubicin (0.70, 0.82 and 0.90 µM, respectively) with more than three folds higher selectivity index against the Caco2 cell lines. Compound 9 prevented the healing of the cancer cells at a low concentration. Also, the compound’s potential to induce programmed cell death in Caco-2 was proved through the significant down regulating of the expression of Bcl2, Bcl-xl and Survivin in addition to the slight upregulation of the TGF-β gene. The cell cycle analysis indicated that compound 9 arrested the Caco-2 cells in the G2/M phase. Interestingly, the molecular docking studies against VEGFR-2 revealed the correct binding of the targeted compounds similar to sorafenib. Furthermore, MD experiments validated the binding of compound 12 with VEGFR-2 over 100 ns, as well as MM-PBSA analysis that confirmed the precise binding with optimum energy. Finally, ADMET analysis showed the general drug-likeness and confirmed the safety of the tested compounds.Communicated by Ramaswamy H. Sarma
Journal of Enzyme Inhibition and Medicinal Chemistry · مجلد 37 (1) · 2191-2205
New quinoline and isatin derivatives having the main characteristics of VEGFR-2 inhibitors was synthesised. The antiproliferative effects of these compounds were estimated against A549, Caco-2, HepG2, and MDA-MB-231. Compounds 13 and 14 showed comparable activities with doxorubicin against the Caco-2 cells. These compounds strongly inhibited VEGFR-2 kinase activity. The cytotoxic activities were evaluated against Vero cells. Compound 7 showed the highest value of safety and selectivity. Cell migration assay displayed the ability of compound 7 to prevent healing and migration abilities in the cancer cells. Furthermore, compound 7 induced apoptosis in Caco-2 through the expressive down-regulation of the apoptotic genes, Bcl2, Bcl-xl, and Survivin, and the upregulation of the TGF gene. Molecular docking against VEGFR-2 emerged the interactions of the synthesised compounds in a similar way to sorafenib. Additionally, seven molecular dynamics simulations studies were applied and confirmed the stability of compound 13 in the active pocket of VEGFR-2 over 100 ns.
The purpose of the study was to develop an SNEDDS to improve the solubility and bioavailability of pitavastatin. The solubility of pitavastatin in different oils, surfactants, and co-surfactants was determined and a pseudo-ternary phase diagram was constructed. The SNEDDS was characterized by zeta-sizer, zeta-potential, FTIR, DSC, and TGA. Release and permeation of pitavastatin from the SNEDDS was studied for 12 and 24 h, respectively. The lipolysis test, RBC lysis, effect on lipid profile, and pharmacokinetics were studied. The SPC3 formulation showed a 104 ± 1.50 nm particle size, a 0.198 polydispersity index (PDI), and a –29 zeta potential. FTIR, DSC, and TGA showed the chemical compatibility and thermal stability. The release and permeation of pitavastatin from SPC3 was 88.5 ± 2.5% and 96%, respectively. In the lipolysis test, the digestion of SPC3 yielded a high amount of pitavastatin and showed little RBC lysis. The lipid profile suggested that after 35 days of administration of the SNEDDS, there was a marked decrease in TC, LDL, and triglyceride levels. The SNEDDS of SPC3 showed an 86% viability of Caco-2 cells. Pharmacokinetics of SPC3 showed improved values of Cmax, Tmax, half-life, MRT, AUC, and AUMC compared to the reference formulation. Our study demonstrated that the SNEDDS effectively enhanced the solubility and bioavailability of a BCS class II drug.
pitavastatinself-nanoemulsifying drug delivery systemsolubility enhancementbioavailability enhancement
We report herein, the design and synthesis of thiazolidine-2,4-diones derivatives as new inhibitors for VEGFR-2. The designed members were assessed for their in vitro anticancer activity against four cancer cell lines; A549, Caco-2, HepG-2 and MDA-MB-231. Compound 14a showed the most potent effects against Caco-2, and HepG-2 cell lines (IC50 = of 1.5 and 31.5 μM, respectively). Next, the in vitro VEGFR-2 inhibitory activity, safety profiles and selectivity indices were examined for all the synthesized members against the normal Vero cell line. Compound 14a (the safest member against Caco-2 cell line) was further investigated for its ability to inhibit Caco-2 cells migration and healing. Moreover, the apoptotic induction of compound 14a against Caco-2 cell line was investigated by assessing against four apoptotic genes (Bcl2, Bcl-xl, TGF, and Survivin). The results revealed that compound 14a can exert apoptosis through significant reduction of Bcl2, Survivin, and TGF gene expression levels. Finally, deep computational studies including molecular docking, ADMET, toxicity studies, and MD simulation were carried out. Also, the DFT calculations were performed and discussed, and the results confirmed the inhibitory reactivity of 14a against VEGFR-2. Compound 14a is expected to be used as a potential lead in the development of new VEGFR-2 inhibitors with increased potency.